Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT07219758

RECANA OUS – Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK)

RECANA OUS – Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK) — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07219758.

📅 25 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT07219758
Sponsor
Intervene, Inc.
Start
2025-10-18
ClinicaliQ Trial Snapshot
  • RECANA OUS – Recana Thrombectomy Catheter System for Venous Obstruction and Occlusion Study (RECANA-OUS-UK) — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07219758.
  • The goal of this clinical investigation is to learn if the Recana Thrombectomy Catheter System can treat chronic venous obstruction and occlusion in participants with symptomatic post-thrombotic venous inflow/outflow obstruction. The main questions the clinical investigation aims to answer are: 1. primary….
  • Sponsor: Intervene, Inc.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this clinical investigation is to learn if the Recana Thrombectomy Catheter System can treat chronic venous obstruction and occlusion in participants with symptomatic post-thrombotic venous inflow/outflow obstruction. The main questions the clinical investigation aims to answer are: 1. primary safety endpoint: procedural events defined as the rates of all adverse events occurring up to 30 days post-index procedure 2. primary efficacy endpoint: percent (%) lumen gain during the index procedure, which is measured using intravascular ultrasound (IVUS) at the time of the procedure (perioperative/periprocedural) Participants are screened…

Eligibility Snapshot
  • : 1. Provision of signed and dated informed consent form;
  • Participant is 18 years of age and older; 3. Neurologically stable; 4. Ambulatory; 5. Symptomatic chronic venous insuSciency (CVI), with edema or pain, (CEAP classification of C3 or greater); 6. Flow-limiting venous outflow obstruction (>50%) within the intended target sites, defined by (a) a common femoral vein continuous waveform without respiratory variation on duplex ultrasound, or, (b) complete occlusion of any part of the iliofemoral tract as diagnosed on baseline duplex or axial imaging per local protocol; and 7. Target treatment IVC/Common Iliac confluence to the deep veins above the knee.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessment
Respiratory / COPD / Asthma · 02 Apr 2026
Digital spirometry algorithms can improve diagnostic accuracy for asthma and COPD in primary care and community diagnostic centres, potentially reducing unnecessary referrals…
View guideline →
Clinical Brief
Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines
Respiratory / COPD / Asthma · MHRA · 24 Apr 2025
Healthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with…
View brief →
Guideline
Mepolizumab for Treating Severe Refractory Eosinophilic Asthma (NICE TA431)
Respiratory / COPD / Asthma · 27 Mar 2026
Initiate mepolizumab 100 mg subcutaneously once monthly only in adults with severe eosinophilic asthma inadequately controlled on high-dose inhaled corticosteroids plus long-acting…
View guideline →
Clinical Brief
‘My baby scratches and scratches’: Families say their homes are making their children sick
Respiratory / COPD / Asthma · BBC Health · 23 Apr 2026
Temporary housing conditions are contributing to increased rates of childhood skin conditions (notably atopic dermatitis), with families reporting persistent scratching and distress…
View brief →
Clinical Brief
Asthma and COPD patients to receive better care closer to home
Respiratory / COPD / Asthma · NHS England · 17 Mar 2026
Asthma and chronic obstructive pulmonary disease (COPD) patients will receive better care closer to home under a landmark £10 million partnership. This…
View brief →
Guideline
GINA 2024 Report: Global Strategy for Asthma Management and Prevention
Respiratory / COPD / Asthma · 31 Mar 2026
GINA 2024 reinforces no SABA-only treatment for any asthma severity: all patients should receive ICS-containing controller therapy or ICS-formoterol MART as first-line…
View guideline →